PAIRE
PAIRE automates routine nuclear medicine imaging tasks so nuclear physicians can focus on interpretation and clinical decisions. It applies AI-driven image segmentation, quantification and analytics to produce standardized measurements, reduce inter-reader variance, and provide an immediate second opinion including metrics like TMTV. PAIRE is offered as a B2B SaaS medical imaging tool for nuclear medicine and radiology departments and integrates into clinical workflows and PACS systems. The platform targets hospitals and imaging centers seeking faster reads, consistent metrics, and supplemental AI guidance.
PAIRE
PAIRE automates routine nuclear medicine imaging tasks so nuclear physicians can focus on interpretation and clinical decisions. It applies AI-driven image segmentation, quantification and analytics to produce standardized measurements, reduce inter-reader variance, and provide an immediate second opinion including metrics like TMTV. PAIRE is offered as a B2B SaaS medical imaging tool for nuclear medicine and radiology departments and integrates into clinical workflows and PACS systems. The platform targets hospitals and imaging centers seeking faster reads, consistent metrics, and supplemental AI guidance.
TL;DR
Company: PAIRE — Paris-based deeptech AI for nuclear medicine
Founded: 2021
Flagship product: Pionus — AI software for lesion detection, segmentation and quantification on FDG PET-CT
Regulatory / quality: Reports CE marking (MDR) and ISO 13485 certification
Business model: B2B SaaS for hospitals and imaging centers; integrates with PACS/workflows
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Nuclear medicine imaging — lesion detection, segmentation, quantification and analytics on PET-CT scans.
Founded
2021
Industry
DeepTech
Tech Stack
Funding Track Record
Listed investor and last funding date present in company snapshot